US Epidemiology of Cannabis Use and Associated Problems

Deborah S Hasin, Deborah S Hasin

Abstract

This review provides an overview of the changing US epidemiology of cannabis use and associated problems. Adults and adolescents increasingly view cannabis as harmless, and some can use cannabis without harm. However, potential problems include harms from prenatal exposure and unintentional childhood exposure; decline in educational or occupational functioning after early adolescent use, and in adulthood, impaired driving and vehicle crashes; cannabis use disorders (CUD), cannabis withdrawal, and psychiatric comorbidity. Evidence suggests national increases in cannabis potency, prenatal and unintentional childhood exposure; and in adults, increased use, CUD, cannabis-related emergency room visits, and fatal vehicle crashes. Twenty-nine states have medical marijuana laws (MMLs) and of these, 8 have recreational marijuana laws (RMLs). Many studies indicate that MMLs or their specific provisions did not increase adolescent cannabis use. However, the more limited literature suggests that MMLs have led to increased cannabis potency, unintentional childhood exposures, adult cannabis use, and adult CUD. Ecological-level studies suggest that MMLs have led to substitution of cannabis for opioids, and also possibly for psychiatric medications. Much remains to be determined about cannabis trends and the role of MMLs and RMLs in these trends. The public, health professionals, and policy makers would benefit from education about the risks of cannabis use, the increases in such risks, and the role of marijuana laws in these increases.

Figures

Figure 1
Figure 1
DSM-IV and DSM-5 criteria for cannabis use disorder (CUD).
Figure 2
Figure 2
US states, medical and recreational marijuana laws.

References

    1. Agrawal A, Budney AJ, Lynskey MT (2012). The co-occurring use and misuse of cannabis and tobacco: a review. Addiction 107: 1221–1233.
    1. Agrawal A, Lynskey MT (2006). The genetic epidemiology of cannabis use, abuse and dependence. Addiction 101: 801–812.
    1. Agrawal A, Lynskey MT (2007). Does gender contribute to heterogeneity in criteria for cannabis abuse and dependence? Results from the national epidemiological survey on alcohol and related conditions. Drug Alcohol Depend 88: 300–307.
    1. Agrawal A, Lynskey MT (2014). Cannabis controversies: how genetics can inform the study of comorbidity. Addiction 109: 360–370.
    1. Agrawal A, Neale MC, Prescott CA, Kendler KS (2004). A twin study of early cannabis use and subsequent use and abuse/dependence of other illicit drugs. Psychol Med 34: 1227–1237.
    1. Agrawal A, Pergadia ML, Lynskey MT (2008). Is there evidence for symptoms of cannabis withdrawal in the national epidemiologic survey of alcohol and related conditions? Am J Addict 17: 199–208.
    1. Allsop DJ, Copeland J, Norberg MM, Fu S, Molnar A, Lewis J et al (2012). Quantifying the clinical significance of cannabis withdrawal. PLoS ONE 7: e44864.
    1. American College of Obstetricians, Gynecologists Committee on Obstetric Practice (2015). Committee Opinion No. 637: Marijuana Use During Pregnancy and Lactation. Obstet Gynecol 126: 234–238.
    1. American Psychiatric Association (1994) Diagnostic and Statistical Manual of Mental Disorders, 4th edn. American Psychiatric Association: Washington, DC.
    1. American Psychiatric Association (2013) Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition. American Psychiatric Association: Arlington, VA.
    1. Anderson DM, Hansen B, Rees DI (2013). Medical marijuana laws, traffic fatalities, and alcohol consumption. J Law Econ 56: 333–369.
    1. Anderson DM, Hansen B, Rees DI (2015). Medical marijuana laws and teen marijuana use. Am Law Econ Rev 17: 495–528.
    1. Anderson DM, Rees DI (2014). The legalization of recreational marijuana: how likely is the worst-case scenario? J Policy Anal Manage 33: 221–232.
    1. Angrist J, Krueger AB (1999) Empirical strategies in labor economics. In: Handbook of Labor Economics Vol. 3A. Elsevier: Amsterdam, The Netherlands, Vol. 3A.
    1. Angrist JD, Pischke JS (2009) Mostly Harmless Econometrics: An Empiricist's Companion. Princeton University Press: Princeton.
    1. Anthony JC, Warner LA, Kessler RC (1994). Comparative epidemiology of dependence on tobacco, alcohol, controlled substances, and inhalants: basic findings from the National Comorbidity Survey. Exp Clin Psychopharmacol 2: 244–268.
    1. Asbridge M, Hayden JA, Cartwright JL (2012). Acute cannabis consumption and motor vehicle collision risk: systematic review of observational studies and meta-analysis. BMJ 344: e536.
    1. Azofeifa A, Mattson ME, Grant A (2016. a). Monitoring marijuana use in the United States: challenges in an evolving environment. JAMA 316: 1765–1766.
    1. Azofeifa A, Mattson ME, Schauer G, McAfee T, Grant A, Lyerla R (2016. b). national estimates of marijuana use and related indicators - National Survey on Drug Use and Health, United States, 2002-2014. MMWR Surveill Summ 65: 1–28.
    1. Babor TAlcohol: No Ordinary Commodity. Oxford University Press: New York, 2010.
    1. Bachhuber MA, McGinty EE, Kennedy-Hendricks A, Niederdeppe J, Barry CL (2015). Messaging to increase public support for naloxone distribution policies in the United States: results from a randomized survey experiment. PLoS ONE 10: e0130050.
    1. Bachhuber MA, Saloner B, Cunningham CO, Barry CL (2014). Medical cannabis laws and opioid analgesic overdose mortality in the United States, 1999-2010. JAMA Intern Med 174: 1668–1673.
    1. Bachman JG, Johnson LD, O'Malley PM (1998). Explaining recent increases in students' marijuana use: impacts of perceived risks and disapproval, 1976 through 1996. Am J Public Health 88: 887–892.
    1. Bachman JG, Johnston LD, O’Malley PM, Humphrey RH (1988). Explaining the recent decline in marijuana use: Differentiating the effects of perceived risks, disapproval, and general lifestyle factors. J Health Soc Behav 29: 92–112.
    1. Bahorik AL, Leibowitz A, Sterling SA, Travis A, Weisner C, Satre DD (2017). Patterns of marijuana use among psychiatry patients with depression and its impact on recovery. J Affect Disord 213: 168–171.
    1. Batalla A, Bhattacharyya S, Yucel M, Fusar-Poli P, Crippa JA, Nogue S et al (2013). Structural and functional imaging studies in chronic cannabis users: a systematic review of adolescent and adult findings. PLoS ONE 8: e55821.
    1. Baumann AF, Scheinbaum C (2016). Weed Rosin Is Changing the Way We Get High. Bloomberg Businessweek. Available at . Accessed 3 July 2017.
    1. Blanco C, Hasin DS, Wall MM, Florez-Salamanca L, Hoertel N, Wang S et al (2016). Cannabis use and risk of psychiatric disorders: prospective evidence from a US National Longitudinal Study. JAMA Psychiatry 73: 388–395.
    1. Boden JM, Fergusson DM, Horwood LJ (2007). Anxiety disorders and suicidal behaviours in adolescence and young adulthood: findings from a longitudinal study. Psychol Med 37: 431–440.
    1. Boehnke KF, Litinas E, Clauw DJ (2016). Medical cannabis use is associated with decreased opiate medication use in a retrospective cross-sectional survey of patients with chronic pain. J Pain 17: 739–744.
    1. Bogdan R, Winstone JM, Agrawal A (2016). Genetic and environmental factors associated with cannabis involvement. Curr Addict Rep 3: 199–213.
    1. Bohnert KM, Perron BE, Ashrafioun L, Kleinberg F, Jannausch M, Ilgen MA (2014). Positive posttraumatic stress disorder screens among first-time medical cannabis patients: prevalence and association with other substance use. Addict Behav 39: 1414–1417.
    1. Bonn-Miller MO, Boden MT, Bucossi MM, Babson KA (2014). Self-reported cannabis use characteristics, patterns and helpfulness among medical cannabis users. Am J Drug Alcohol Abuse 40: 23–30.
    1. Bonn-Miller MO, Harris AH, Trafton JA (2012). Prevalence of cannabis use disorder diagnoses among veterans in 2002, 2008, and 2009. Psychol Serv 9: 404–416.
    1. Bradford AC, Bradford WD (2016. a). Medical marijuana laws reduce prescription medication use in Medicare Part D. Health Aff (Millwood) 35: 1230–1236.
    1. Bradford AC, Bradford WD (2016. b). Medical marijuana laws: the authors reply. Health Aff (Millwood) 35: 1937.
    1. Bradford AC, Bradford WD (2017). Medical marijuana laws may be associated with a decline in the number of prescriptions for Medicaid enrollees. Health Aff (Millwood) 36: 945–951.
    1. Brady JE, Li G (2014). Trends in alcohol and other drugs detected in fatally injured drivers in the United States, 1999-2010. Am J Epidemiol 179: 692–699.
    1. Broadly (2016). Why people smoke weed to treat depression. Available at . Accessed 29 June 2017.
    1. Brown QL, Sarvet AL, Shmulewitz D, Martins SS, Wall MM, Hasin DS (2017). Trends in marijuana use among pregnant and nonpregnant reproductive-aged women, 2002-2014. JAMA 317: 207–209.
    1. Budney AJ, Hughes JR (2006). The cannabis withdrawal syndrome. Curr Opin Psychiatry 19: 233–238.
    1. Budney AJ, Hughes JR, Moore BA, Vandrey R (2004). Review of the validity and significance of cannabis withdrawal syndrome. Am J Psychiatry 161: 1967–1977.
    1. Budney AJ, Moore BA, Vandrey RG, Hughes JR (2003). The time course and significance of cannabis withdrawal. J Abnorm Psychol 112: 393–402.
    1. Budney AJ, Vandrey RG, Hughes JR, Moore BA, Bahrenburg B (2007). Oral delta-9-tetrahydrocannabinol suppresses cannabis withdrawal symptoms. Drug Alcohol Depend 86: 22–29.
    1. Budney AJ, Vandrey RG, Hughes JR, Thostenson JD, Bursac Z (2008). Comparison of cannabis and tobacco withdrawal: severity and contribution to relapse. J Subst Abuse Treat 35: 362–368.
    1. Bujarski SJ, Galang JN, Short NA, Trafton JA, Gifford EV, Kimerling R et al (2016). Cannabis use disorder treatment barriers and facilitators among veterans with PTSD. Psychol Addict Behav 30: 73–81.
    1. Calabria B, Degenhardt L, Hall W, Lynskey M (2010). Does cannabis use increase the risk of death? Systematic review of epidemiological evidence on adverse effects of cannabis use. Drug Alcohol Rev 29: 318–330.
    1. Cambron C, Guttmannova K, Fleming CB (2017). State and national contexts in evaluating cannabis laws: a case study of Washington state. J Drug Issues 47: 74–90.
    1. Carey CE, Agrawal A, Bucholz KK, Hartz SM, Lynskey MT, Nelson EC et al (2016). Associations between polygenic risk for psychiatric disorders and substance involvement. Front Genet 7: 149.
    1. Carliner H, Mauro PM, Brown QL, Shmulewitz D, Rahim-Juwel R, Sarvet AL et al (2017). The widening gender gap in marijuana use prevalence in the U.S. during a period of economic change, 2002-2014. Drug Alcohol Depend 170: 51–58.
    1. Carnevale JT, Kagan R, Murphy PJ, Esrick J (2017). A practical framework for regulating for-profit recreational marijuana in US states: lessons from Colorado and Washington. Int J Drug Policy 42: 71–85.
    1. Carney R, Cotter J, Firth J, Bradshaw T, Yung AR (2017). Cannabis use and symptom severity in individuals at ultra high risk for psychosis: a meta-analysis. Acta Psychiatr Scand 136: 5–15.
    1. Cascini F, Aiello C, Di Tanna G (2012). Increasing delta-9-tetrahydrocannabinol (Delta-9-THC) content in herbal cannabis over time: systematic review and meta-analysis. Curr Drug Abuse Rev 5: 32–40.
    1. Cerda M, Wall M, Feng T, Keyes KM, Sarvet A, Schulenberg J et al (2017). Association of state recreational marijuana laws with adolescent marijuana use. JAMA Pediatr 171: 142–149.
    1. Cerda M, Wall M, Keyes KM, Galea S, Hasin D (2012). Medical marijuana laws in 50 states: investigating the relationship between state legalization of medical marijuana and marijuana use, abuse and dependence. Drug Alcohol Depend 120: 22–27.
    1. Charilaou P, Agnihotri K, Garcia P, Badheka A, Frenia D, Yegneswaran B (2017). Trends of cannabis use disorder in the inpatient: 2002 to 2011. Am J Med 130: 678–687 e677.
    1. Chen CY, Storr CL, Anthony JC (2009). Early-onset drug use and risk for drug dependence problems. Addict Behav 34: 319–322.
    1. Choi A (2014) The Impact of Medical Marijuana Laws on Marijuana Use And Other Risky Health Behaviors. Presented at the American Society for Health Economics, Los Angeles, CA.
    1. Choo EK, Feldstein Ewing SW, Lovejoy TI (2016). Opioids out, cannabis in: negotiating the unknowns in patient care for chronic pain. JAMA 316: 1763–1764.
    1. Chou R, Deyo R, Devine B, Hansen R, Sullivan S, Jarvik JG et al (2014). The Effectiveness and Risks of Long-Term Opioid Treatment of Chronic Pain. AHRQ Publication No. 14-E005-EF. Agency for Healthcare Research and Quality: Rockville, MD. Available at Accessed 1 June 2017.
    1. Chu YW (2014). The effects of medical marijuana laws on illegal marijuana use. J Health Econ 38: 43–61.
    1. Chung T, Martin CS, Cornelius JR, Clark DB (2008). Cannabis withdrawal predicts severity of cannabis involvement at 1-year follow-up among treated adolescents. Addiction 103: 787–799.
    1. CNN (2016). Colorado marijuana's potency getting 'higher'. Available at Accessed 2 July 2017.
    1. Compton WM, Han B, Hughes A, Jones CM, Blanco C (2017). Use of marijuana for medical purposes among adults in the United States. JAMA 317: 209–211.
    1. Compton WM, Han B, Jones CM, Blanco C, Hughes A (2016). Marijuana use and use disorders in adults in the USA, 2002-14: analysis of annual cross-sectional surveys. Lancet Psychiatry 3: 954–964.
    1. Compton WM, Saha TD, Conway KP, Grant BF (2009). The role of cannabis use within a dimensional approach to cannabis use disorders. Drug Alcohol Depend 100: 221–227.
    1. Connell CM, Gilreath TD, Aklin WM, Brex RA (2010). Social-ecological influences on patterns of substance use among non-metropolitan high school students. Am J Community Psychol 45: 36–48.
    1. Copersino ML, Boyd SJ, Tashkin DP, Huestis MA, Heishman SJ, Dermand JC et al (2006). Cannabis withdrawal among non-treatment-seeking adult cannabis users. Am J Addict 15: 8–14.
    1. Corbett KK (2001). Susceptibility of youth to tobacco: a social ecological framework for prevention. Respir Physiol 128: 103–118.
    1. Cornelius JR, Chung T, Martin C, Wood DS, Clark DB (2008). Cannabis withdrawal is common among treatment-seeking adolescents with cannabis dependence and major depression, and is associated with rapid relapse to dependence. Addict Behav 33: 1500–1505.
    1. Corroon JM Jr, Mischley LK, Sexton M (2017). Cannabis as a substitute for prescription drugs - a cross-sectional study. J Pain Res 10: 989–998.
    1. Davis AK, Bonar EE, Ilgen MA, Walton MA, Perron BE, Chermack ST (2016. a). Factors associated with having a medical marijuana card among veterans with recent substance use in VA outpatient treatment. Addict Behav 63: 132–136.
    1. Davis JM, Mendelson B, Berkes JJ, Suleta K, Corsi KF, Booth RE (2016. b). Public health effects of medical marijuana legalization in Colorado. Am J Prev Med 50: 373–379.
    1. Edwards G (1974). Cannabis and the criteria for legalisation of a currently prohibited recreational drug: groundwork for a debate. Acta Psychiatr Scand Suppl 251: 1–62.
    1. El Marroun H, Tiemeier H, Franken IH, Jaddoe VW, van der Lugt A, Verhulst FC et al (2016). Prenatal cannabis and tobacco exposure in relation to brain morphology: a prospective neuroimaging study in young children. Biol Psychiatry 79: 971–979.
    1. Elkashef A, Vocci F, Huestis M, Haney M, Budney A, Gruber A et al (2008). Marijuana neurobiology and treatment. Subst Abus 29: 17–29.
    1. ElSohly MA, Mehmedic Z, Foster S, Gon C, Chandra S, Church JC (2016). Changes in cannabis potency over the last 2 decades (1995-2014): analysis of current data in the United States. Biol Psychiatry 79: 613–619.
    1. Englund A, Freeman TP, Murray RM, McGuire P (2017). Can we make cannabis safer? Lancet Psychiatry 4: 643–648.
    1. Fergusson DM, Boden JM (2008). Cannabis use and later life outcomes. Addiction 103: 969–976 discussion 977-968.
    1. Fergusson DM, Boden JM, Horwood LJ (2015). Psychosocial sequelae of cannabis use and implications for policy: findings from the Christchurch Health and Development Study. Soc Psychiatry Psychiatr Epidemiol 50: 1317–1326.
    1. Finney JW, Humphreys K, Harris AH (2015). What ecologic analyses cannot tell us about medical marijuana legalization and opioid pain medication mortality. JAMA Intern Med 175: 655–656.
    1. Forbes (2017). $1 Billion in Marijuana Taxes Is Addictive to State Governors. Available athttps:// Accessed 30 June 2017.
    1. Fortune (2016). Colorado Topped $1 Billion in Legal Marijuana Sales in 2016. Available athttp:// Accessed 30 June 2017.
    1. Gage SH, Hickman M, Zammit S (2016). Association between cannabis and psychosis: epidemiologic evidence. Biol Psychiatry 79: 549–556.
    1. Garg RK, Fulton-Kehoe D, Franklin GM (2017). Patterns of opioid use and risk of opioid overdose death among Medicaid patients. Med Care 55: 661–668.
    1. Goldstein RZ, Volkow ND (2011). Dysfunction of the prefrontal cortex in addiction: neuroimaging findings and clinical implications. Nat Rev Neurosci 12: 652–669.
    1. Grant BF (1996). DSM-IV, DSM-III-R, and ICD-10 alcohol and drug abuse/harmful use and dependence, United States, 1992: a nosological comparison. Alcohol Clin Exp Res 20: 1481–1488.
    1. Grass City (2010). Marijuana cured my depression. Available athttps://. Accessed 29 June 2017.
    1. Greene MC, Kelly JF (2014). The prevalence of cannabis withdrawal and its influence on adolescents' treatment response and outcomes: a 12-month prospective investigation. J Addict Med 8: 359–367.
    1. Grucza RA, Agrawal A, Bierut LJ (2016. a). NESARC findings on increased prevalence of marijuana use disorders-reply: consistent with other sources of information. JAMA Psychiatry 73: 532–533.
    1. Grucza RA, Agrawal A, Krauss MJ, Bongu J, Plunk AD, Cavazos-Rehg PA et al (2016. b). declining prevalence of marijuana use disorders among adolescents in the United States, 2002 to 2013. J Am Acad Child Adolesc Psychiatry 55: 487–494 e486.
    1. Grucza RA, Agrawal A, Krauss MJ, Cavazos-Rehg PA, Bierut LJ (2016. c). Recent trends in the prevalence of marijuana use and associated disorders in the United States. JAMA Psychiatry 73: 300–301.
    1. Gruenewald PJ (2011). Regulating availability: how access to alcohol affects drinking and problems in youth and adults. Alcohol Res Health 34: 248–256.
    1. Gruenewald PJ, Remer LG, LaScala EA (2014). Testing a social ecological model of alcohol use: the California 50-city study. Addiction 109: 736–745.
    1. Gubatan J, Staller K, Barshop K, Kuo B (2016). Cannabis abuse is increasing and associated with increased emergency department utilization in gastroenterology patients. Dig Dis Sci 61: 1844–1852.
    1. Gunn JK, Rosales CB, Center KE, Nunez A, Gibson SJ, Christ C et al (2016). Prenatal exposure to cannabis and maternal and child health outcomes: a systematic review and meta-analysis. BMJ Open 6: e009986.
    1. Guttmannova K, Lee CM, Kilmer JR, Fleming CB, Rhew IC, Kosterman R et al (2016). Impacts of changing marijuana policies on alcohol use in the United States. Alcohol Clin Exp Res 40: 33–46.
    1. Haberstick BC, Zeiger JS, Corley RP, Hopfer CJ, Stallings MC, Rhee SH et al (2011). Common and drug-specific genetic influences on subjective effects to alcohol, tobacco and marijuana use. Addiction 106: 215–224.
    1. Hall W (2017). Alcohol and cannabis: comparing their adverse health effects and regulatory regimes. Int J Drug Policy 42: 57–62.
    1. Hall W, Lynskey M (2016). Evaluating the public health impacts of legalizing recreational cannabis use in the United States. Addiction 111: 1764–1773.
    1. Hall W, Renström M, Poznyak V (2016) The Health and Social Effects of Nonmedical Cannabis Use. World Health Organization: Geneva.
    1. Haney M, Bedi G, Cooper ZD, Glass A, Vosburg SK, Comer SD et al (2013). Predictors of marijuana relapse in the human laboratory: robust impact of tobacco cigarette smoking status. Biol Psychiatry 73: 242–248.
    1. Haney M, Evins AE (2016). Does cannabis cause, exacerbate or ameliorate psychiatric disorders? An oversimplified debate discussed. Neuropsychopharmacology 41: 393–401.
    1. Haney M, Hart CL, Vosburg SK, Nasser J, Bennett A, Zubaran C et al (2004). Marijuana withdrawal in humans: effects of oral THC or divalproex. Neuropsychopharmacology 29: 158–170.
    1. Hardt J, Jacobsen C, Goldberg J, Nickel R, Buchwald D (2008). Prevalence of chronic pain in a representative sample in the United States. Pain Med 9: 803–812.
    1. Harris D, Jones RT, Shank R, Nath R, Fernandez E, Goldstein K et al (2000). Self-reported marijuana effects and characteristics of 100 San Francisco medical marijuana club members. J Addict Dis 19: 89–103.
    1. Hartman RL, Huestis MA (2013). Cannabis effects on driving skills. Clin Chem 59: 478–492.
    1. Hasin D, Grant BF, Cottler L, Blaine J, Towle L, Ustun B et al (1997). Nosological comparisons of alcohol and drug diagnoses: a multisite, multi-instrument international study. Drug Alcohol Depend 47: 217–226.
    1. Hasin D, Hatzenbuehler ML, Keyes K, Ogburn E (2006). Substance use disorders: Diagnostic and Statistical Manual of Mental Disorders, fourth edition (DSM-IV) and International Classification of Diseases, tenth edition (ICD-10). Addiction 101(Suppl 1): 59–75.
    1. Hasin DS, Grant B (2016). NESARC findings on increased prevalence of marijuana use disorders-consistent with other sources of information. JAMA Psychiatry 73: 532.
    1. Hasin DS, Kerridge BT, Saha TD, Huang B, Pickering R, Smith SM et al (2016). Prevalence and correlates of DSM-5 cannabis use disorder, 2012-2013: findings from the National Epidemiologic Survey on Alcohol and Related Conditions-III. Am J Psychiatry 173: 588–599.
    1. Hasin DS, Keyes KM, Alderson D, Wang S, Aharonovich E, Grant BF (2008). Cannabis withdrawal in the United States: results from NESARC. J Clin Psychiatry 69: 1354–1363.
    1. Hasin DS, O'Brien CP, Auriacombe M, Borges G, Bucholz K, Budney A et al (2013). DSM-5 criteria for substance use disorders: recommendations and rationale. Am J Psychiatry 170: 834–851.
    1. Hasin DS, Saha TD, Kerridge BT, Goldstein RB, Chou SP, Zhang H et al (2015. a). Prevalence of marijuana use disorders in the United States between 2001-2002 and 2012-2013. JAMA Psychiatry 72: 1235–1242.
    1. Hasin DS, Sarvet AL, Cerdá M, Keyes KM, Stohl M, Galea S et al (2017). US adult illicit cannabis use, cannabis disorder, and medical marijuana laws: 1991-1992 to 2012-2013. JAMA Psychiatry 74: 579–588.
    1. Hasin DS, Wall M, Keyes KM, Cerda M, Schulenberg J, O'Malley PM et al (2015. b). Medical marijuana laws and adolescent marijuana use in the USA from 1991 to 2014: results from annual, repeated cross-sectional surveys. Lancet Psychiatry 2: 601–608.
    1. Haug NA, Padula CB, Sottile JE, Vandrey R, Heinz AJ, Bonn-Miller MO (2017). Cannabis use patterns and motives: a comparison of younger, middle-aged, and older medical cannabis dispensary patients. Addict Behav 72: 14–20.
    1. Hawken A, Caulkins J, Kilmer B, Kleiman M (2013). Quasi-legal cannabis in Colorado and Washington: local and national implications. Addiction 108: 837–838.
    1. Hawkins EJ, Malte CA, Grossbard J, Saxon AJ, Imel ZE, Kivlahan DR (2013). Comparative safety of benzodiazepines and opioids among veterans affairs patients with posttraumatic stress disorder. J Addict Med 7: 354–362.
    1. Hawkins EJ, Malte CA, Grossbard JR, Saxon AJ (2015). Prevalence and trends of concurrent opioid analgesic and benzodiazepine use among Veterans Affairs patients with post-traumatic stress disorder, 2003-2011. Pain Med 16: 1943–1954.
    1. Hayes MJ, Brown MS (2014). Legalization of medical marijuana and incidence of opioid mortality. JAMA Intern Med 174: 1673–1674.
    1. Hodgson K, Almasy L, Knowles EE, Kent JW Jr, Curran JE, Dyer TD et al (2017). The genetic basis of the comorbidity between cannabis use and major depression. Addiction 112: 113–123.
    1. Hunt PE, Miles J (2015). The Impact of legalizing and regulating weed: issues with study design and emerging findings in the USA. Curr Top Behav Neurosci 34: 173–198.
    1. Hwang CS, Kang EM, Kornegay CJ, Staffa JA, Jones CM, McAninch JK (2016). Trends in the concomitant prescribing of opioids and benzodiazepines, 2002-2014. Am J Prev Med 51: 151–160.
    1. Imbens GW, Wooldridge JM (2009). Recent developments in the econometrics of program evaluation. J Econ Lit 47: 5–86.
    1. Institute of Medicine (2011) Relieving Pain in America: A Blueprint for Transforming Prevention, Care, Education, and Research. National Academies Press (US): Washington, DC.
    1. Janz NK, Becker MH (1984). The Health Belief Model: a decade later. Health Educ Q 11: 1–47.
    1. Jehle CC Jr, Nazir N, Bhavsar D (2015). The rapidly increasing trend of cannabis use in burn injury. J Burn Care Res 36: e12–e17.
    1. Johnson MB, Kelley-Baker T, Voas RB, Lacey JH (2012). The prevalence of cannabis-involved driving in California. Drug Alcohol Depend 123: 105–109.
    1. Johnston LD, Bachman JG, O'Malley PM (1981) Highlights from Student Drug Use in America, 1975–1980.
    1. Joy JE, Watson SJ, Benson JA (2017) Marijuana and Medicine: Assessing the Science Base. National Academies Press: Washington, DC.
    1. Katz G, Lobel T, Tetelbaum A, Raskin S (2014). Cannabis withdrawal - a new diagnostic category in DSM-5. Isr J Psychiatry Relat Sci 51: 270–275.
    1. Keyes KM, Wall M, Cerda M, Schulenberg J, O'Malley PM, Galea S et al (2016). How does state marijuana policy affect US youth? Medical marijuana laws, marijuana use and perceived harmfulness: 1991-2014. Addiction 111: 2187–2195.
    1. Kilmer B (2017). Recreational cannabis - minimizing the health risks from legalization. N Engl J Med 376: 705–707.
    1. Kim JH, Santaella-Tenorio J, Mauro C, Wrobel J, Cerda M, Keyes KM et al (2016). State medical marijuana laws and the prevalence of opioids detected among fatally injured drivers. Am J Public Health 106: 2032–2037.
    1. Ko JY, Farr SL, Tong VT, Creanga AA, Callaghan WM (2015). Prevalence and patterns of marijuana use among pregnant and nonpregnant women of reproductive age. Am J Obstet Gynecol 213: 201 e201–201 e210.
    1. Kouri EM, Pope HG Jr (2000). Abstinence symptoms during withdrawal from chronic marijuana use. Exp Clin Psychopharmacol 8: 483–492.
    1. Kraan T, Velthorst E, Koenders L, Zwaart K, Ising HK, van den Berg D et al (2016). Cannabis use and transition to psychosis in individuals at ultra-high risk: review and meta-analysis. Psychol Med 46: 673–681.
    1. Lee D, Vandrey R, Milman G, Bergamaschi M, Mendu DR, Murray JA et al (2013). Oral fluid/plasma cannabinoid ratios following controlled oral THC and smoked cannabis administration. Anal Bioanal Chem 405: 7269–7279.
    1. Levin KH, Copersino ML, Heishman SJ, Liu F, Kelly DL, Boggs DL et al (2010). Cannabis withdrawal symptoms in non-treatment-seeking adult cannabis smokers. Drug Alcohol Depend 111: 120–127.
    1. Levy B, Paulozzi L, Mack KA, Jones CM (2015). Trends in opioid analgesic-prescribing rates by specialty, U.S., 2007-2012. Am J Prev Med 49: 409–413.
    1. Li MC, Brady JE, DiMaggio CJ, Lusardi AR, Tzong KY, Li G (2012). Marijuana use and motor vehicle crashes. Epidemiol Rev 34: 65–72.
    1. Lichtman AH, Martin BR (2002). Marijuana withdrawal syndrome in the animal model. J Clin Pharmacol 42(11 Suppl): 20S–27S.
    1. Lin LA, Ilgen MA, Jannausch M, Bohnert KM (2016). Comparing adults who use cannabis medically with those who use recreationally: Results from a national sample. Addict Behav 61: 99–103.
    1. Liu C, Huang Y, Pressley JC (2016). Restraint use and risky driving behaviors across drug types and drug and alcohol combinations for drivers involved in a fatal motor vehicle collision on U.S. roadways. Inj Epidemiol 3: 9.
    1. Lucas P, Walsh Z (2017). Medical cannabis access, use, and substitution for prescription opioids and other substances: a survey of authorized medical cannabis patients. Int J Drug Policy 42: 30–35.
    1. Lucas P, Walsh Z, Crosby K, Callaway R, Belle-Isle L, Kay R et al (2016). Substituting cannabis for prescription drugs, alcohol and other substances among medical cannabis patients: the impact of contextual factors. Drug Alcohol Rev 35: 326–333.
    1. Marsot A, Audebert C, Attolini L, Lacarelle B, Micallef J, Blin O (2016). Comparison of cannabinoid concentrations in plasma, oral fluid and urine in occasional cannabis smokers after smoking cannabis cigarette. J Pharm Pharm Sci 19: 411–422.
    1. Martinez D, Kim JH, Krystal J, Abi-Dargham A (2007). Imaging the neurochemistry of alcohol and substance abuse. Neuroimaging Clin N Am 17: 539–555.
    1. Martins SS, Mauro CM, Santaella-Tenorio J, Kim JH, Cerda M, Keyes KM et al (2016). State-level medical marijuana laws, marijuana use and perceived availability of marijuana among the general U.S. population. Drug Alcohol Depend 169: 26–32.
    1. McGinty EE, Niederdeppe J, Heley K, Barry CL (2017. a). Public perceptions of arguments supporting and opposing recreational marijuana legalization. Prev Med 99: 80–86.
    1. McGinty EE, Samples H, Bandara SN, Saloner B, Bachhuber MA, Barry CL (2016). The emerging public discourse on state legalization of marijuana for recreational use in the US: analysis of news media coverage, 2010-2014. Prev Med 90: 114–120.
    1. McGinty EE, Tung G, Shulman-Laniel J, Hardy R, Rutkow L, Frattaroli S et al (2017. b). ignition interlock laws: effects on fatal motor vehicle crashes, 1982-2013. Am J Prev Med 52: 417–423.
    1. McKay MP, Groff L (2016). 23 years of toxicology testing fatally injured pilots: implications for aviation and other modes of transportation. Accid Anal Prev 90: 108–117.
    1. Meier MH, Caspi A, Ambler A, Harrington H, Houts R, Keefe RS et al (2012). Persistent cannabis users show neuropsychological decline from childhood to midlife. Proc Natl Acad Sci USA 109: E2657–E2664.
    1. Milin R, Manion I, Dare G, Walker S (2008). Prospective assessment of cannabis withdrawal in adolescents with cannabis dependence: a pilot study. J Am Acad Child Adolesc Psychiatry 47: 174–178.
    1. The Monitoring the Future study, the University of Michigan (2016). Figures 3 and 4, Marijuana: Trends in annual and daily use in Grades 8, 10 and 12. University of Michigan News Service. Available at: Accessed 22 March 2017.
    1. Musto DF (1991). Opium, cocaine and marijuana in American history. Sci Am 265: 40–47.
    1. Nahin RL (2015). Estimates of pain prevalence and severity in adults: United States, 2012. J Pain 16: 769–780.
    1. National Academies of Sciences, Engineering, and Medicine (2017) The Health Effects of Cannabis and Cannabinoids: The Current State of Evidence and Recommendations for Research. The National Academies Press: Washington, DC.
    1. National Institute on Drug Abuse (2015). 2016-2020 NIDA Strategic Plan. Available at Accessed 28 March 2017.
    1. National Institute on Drug Abuse (2017). Is marijuana addictive? Available at Accessed 2 July 2017.
    1. National Institutes of Health (2015). Adolescent brain cognitive development study. Available at Accessed 1 April 2017.
    1. The New York Times (2017). A balm when you're expecting: sometimes pot does the trick. Available at .
    1. Niederdeppe J, Avery R, Miller EN (2017. a). Alcohol-control PSAs and drunk-driving fatal accidents in the United States, 1996-2010. Prev Med 99: 320–325.
    1. Niederdeppe J, Kellogg M, Skurka C, Avery RJ (2017. b). Market-level exposure to state antismoking media campaigns and public support for tobacco control policy in the United States, 2001-2002. Tob Control.
    1. Nunberg H, Kilmer B, Pacula RL, Burgdorf J (2011). An analysis of applicants presenting to a medical marijuana specialty practice in California. J Drug Policy Anal 4: pii: 1.
    1. O'Connell TJ, Bou-Matar CB (2007). Long term marijuana users seeking medical cannabis in California (2001-2007): demographics, social characteristics, patterns of cannabis and other drug use of 4117 applicants. Harm Reduct J 4: 16.
    1. Ogden DW (2009). Memorandum for Selected United States Attorneys on Investigations and Prosecutions in States Authorizing the Medical Use of Marijuana. The United States Department of Justice Archives. Available at. . Accessed 20 March 2017.
    1. Okie S (2010). A flood of opioids, a rising tide of deaths. N Engl J Med 363: 1981–1985.
    1. Onders B, Casavant MJ, Spiller HA, Chounthirath T, Smith GA (2016). Marijuana exposure among children younger than six years in the United States. Clin Pediatr (Phila) 55: 428–436.
    1. Pacek LR, Mauro PM, Martins SS (2015). Perceived risk of regular cannabis use in the United States from 2002 to 2012: differences by sex, age, and race/ethnicity. Drug Alcohol Depend 149: 232–244.
    1. Pacula RL, Powell D, Heaton P, Sevigny EL (2013). Assessing the effects of marijuana on marijuana and alcohol use: the devil is in the details. Available at . Accessed 16 May 2016.
    1. Pacula RL, Powell D, Heaton P, Sevigny EL (2015). Assessing the effects of medical marijuana laws on marijuana use: the devil is in the details. J Policy Anal Manage 34: 7–31.
    1. Pacula RL, Sevigny EL (2014). Natural experiments in a complex and dynamic environment: the need for a measured assessment of the evidence. J Policy Anal Manage 33: 232–235.
    1. Palamar JJ, Ompad DC, Petkova E (2014). Correlates of intentions to use cannabis among US high school seniors in the case of cannabis legalization. Int J Drug Policy 25: 424–435.
    1. Pardo B (2016). Do more robust prescription drug monitoring programs reduce prescription opioid overdose? Addiction 112: 1773–1783.
    1. Paulozzi LJ, Kilbourne EM, Shah NG, Nolte KB, Desai HA, Landen MG et al (2012). A history of being prescribed controlled substances and risk of drug overdose death. Pain Med 13: 87–95.
    1. Penetar DM, Kouri EM, Gross MM, McCarthy EM, Rhee CK, Peters EN et al (2005). Transdermal nicotine alters some of marihuana's effects in male and female volunteers. Drug Alcohol Depend 79: 211–223.
    1. Piontek D, Kraus L, Bjarnason T, Demetrovics Z, Ramstedt M (2013). Individual and country-level effects of cannabis-related perceptions on cannabis use. A multilevel study among adolescents in 32 European countries. J Adolesc Health 52: 473–479.
    1. Piper BJ, DeKeuster RM, Beals ML, Cobb CM, Burchman CA, Perkinson L et al (2017). Substitution of medical cannabis for pharmaceutical agents for pain, anxiety, and sleep. J Psychopharmacol 31: 569–575.
    1. Powell D, Pacula R, Jacobson M (2015). Do medical marijuana laws reduce addictions and deaths related to pain killers? Available at .
    1. Price ZS (2014). Enforcement discretion and executive duty. Vanderbilt Law Rev 67: 671–769.
    1. Pull CB, Saunders JB, Mavreas V, Cottler LB, Grant BF, Hasin DS et al (1997). Concordance between ICD-10 alcohol and drug use disorder criteria and diagnoses as measured by the AUDADIS-ADR, CIDI and SCAN: results of a cross-national study. Drug Alcohol Depend 47: 207–216.
    1. Rabin RA, George TP (2015). A review of co-morbid tobacco and cannabis use disorders: possible mechanisms to explain high rates of co-use. Am J Addict 24: 105–116.
    1. Ramaekers JG, Berghaus G, van Laar M, Drummer OH (2004). Dose related risk of motor vehicle crashes after cannabis use. Drug Alcohol Depend 73: 109–119.
    1. Reiman A (2009). Cannabis as a substitute for alcohol and other drugs. Harm Reduct J 6: 35.
    1. Reinarman C, Nunberg H, Lanthier F, Heddleston T (2011). Who are medical marijuana patients? Population characteristics from nine California assessment clinics. J Psychoactive Drugs 43: 128–135.
    1. Rogeberg O, Elvik R (2016). The effects of cannabis intoxication on motor vehicle collision revisited and revised. Addiction 111: 1348–1359.
    1. Rounsaville BJ, Bryant K, Babor T, Kranzler H, Kadden R (1993). Cross system agreement for substance use disorders: DSM-III-R, DSM-IV and ICD-10. Addiction 88: 337–348.
    1. Rudd RA, Aleshire N, Zibbell JE, Gladden RM (2016). Increases in drug and opioid overdose deaths—United States, 2000-2014. MMWR Morb Mortal Wkly Rep 64: 1378–1382.
    1. Salomonsen-Sautel S, Min SJ, Sakai JT, Thurstone C, Hopfer C (2014). Trends in fatal motor vehicle crashes before and after marijuana commercialization in Colorado. Drug Alcohol Depend 140: 137–144.
    1. San Nicolas AC, Lemos NP (2015). Toxicology findings in cases of hanging in the city and county of San Francisco over the 3-year period from 2011 to 2013. Forensic Sci Int 255: 146–155.
    1. Santaella-Tenorio J, Mauro CM, Wall MM, Kim JH, Cerda M, Keyes KM et al (2017). US traffic fatalities, 1985-2014, and their relationship to medical marijuana laws. Am J Public Health 107: 336–342.
    1. Sarvet A, Wall M, Fink DS, Greene E, Le A, Boustead AE et al (under review-a). Medical marijuana laws and adolescent marijuana use: a systematic review.
    1. Sarvet AL, Wall MM, Keyes KM, Olfson M, Cerda M, Hasin DS (under review-b). Self-medication of mood and anxiety disorders with marijuana: higher in states with medical marijuana laws.
    1. Saunders JB (2017). Substance use and addictive disorders in DSM-5 and ICD 10 and the draft ICD 11. Curr Opin Psychiatry 30: 227–237.
    1. Saxon AJ, Browne KW (2014). Marijuana not ready for prime time as an analgesic. Gen Hosp Psychiatry 36: 4–6.
    1. Schmidt LA, Jacobs LM, Spetz J (2016). Young people's more permissive views about marijuana: local impact of state laws or national trend? Am J Public Health 106: 1498–1503.
    1. Schuermeyer J, Salomonsen-Sautel S, Price RK, Balan S, Thurstone C, Min SJ et al (2014). Temporal trends in marijuana attitudes, availability and use in Colorado compared to non-medical marijuana states: 2003-11. Drug Alcohol Depend 140: 145–155.
    1. Sevigny EL, Pacula RL, Heaton P (2014). The effects of medical marijuana laws on potency. Int J Drug Policy 25: 308–319.
    1. Sherva R, Wang Q, Kranzler H, Zhao H, Koesterer R, Herman A et al (2016). Genome-wide association study of cannabis dependence severity, novel risk variants, and shared genetic risks. JAMA Psychiatry 73: 472–480.
    1. Shi Y (2017). Medical marijuana policies and hospitalizations related to marijuana and opioid pain reliever. Drug Alcohol Depend 173: 144–150.
    1. Smart R (2015). The Kids Aren't Alright but Older Adults Are Just Fine: Effects of Medical Marijuana Market Growth on Substance Use and Abuse. S. S. R. Network. Available at .
    1. Smolkina M, Morley KI, Rijsdijk F, Agrawal A, Bergin JE, Nelson EC et al (2017). Cannabis and depression: a twin model approach to co-morbidity. Behav Genet 47: 394–404.
    1. Stern TA, Gross AF, Stern TW, Nejad SH, Maldonado JR (2010). Current approaches to the recognition and treatment of alcohol withdrawal and delirium tremens: "old wine in new bottles" or "new wine in old bottles". Prim Care Companion J Clin Psychiatry 12: pii: PCC.10r00991.
    1. Stinson FS, Ruan WJ, Pickering R, Grant BF (2006). Cannabis use disorders in the USA: prevalence, correlates and co-morbidity. Psychol Med 36: 1447–1460.
    1. Substance Abuse and Mental Health Services Administration, Center for Behavioral Health Statistics and Quality (2015). Treatment Episode Data Set (TEDS): 2003-2013. National Admissions to Substance Abuse Treatment Services. Rockville, MD: Substance Abuse and Mental Health Services Administration. Available at .
    1. Sun EC, Dixit A, Humphreys K, Darnall BD, Baker LC, Mackey S (2017). Association between concurrent use of prescription opioids and benzodiazepines and overdose: retrospective analysis. BMJ 356: j760.
    1. Swaim RC (2003). Individual and school level effects of perceived harm, perceived availability, and community size on marijuana use among 12th-grade students: a random effects model. Prev Sci 4: 89–98.
    1. Swift W, Gates P, Dillon P (2005). Survey of Australians using cannabis for medical purposes. Harm Reduct J 2: 18.
    1. Tashkin D (2015). How beneficial is vaping cannabis to respiratory health compared to smoking? Addiction 110: 1706–1707.
    1. Thomas BF, Pollard GT (2016). Preparation and distribution of cannabis and cannabis-derived dosage formulations for investigational and therapeutic use in the United States. Front Pharmacol 7: 285.
    1. Tsang A, Von Korff M, Lee S, Alonso J, Karam E, Angermeyer MC et al (2008). Common chronic pain conditions in developed and developing countries: gender and age differences and comorbidity with depression-anxiety disorders. J Pain 9: 883–891.
    1. U.S. Department of Justice, Drug Enforcement Administration (2017). Controlled substance schedules. Available at: Accessed 15 March 2017.
    1. Ustun B, Compton W, Mager D, Babor T, Baiyewu O, Chatterji S et al (1997). WHO Study on the reliability and validity of the alcohol and drug use disorder instruments: overview of methods and results. Drug Alcohol Depend 47: 161–169.
    1. Verweij KJ, Agrawal A, Nat NO, Creemers HE, Huizink AC, Martin NG et al (2013. a). A genetic perspective on the proposed inclusion of cannabis withdrawal in DSM-5. Psychol Med 43: 1713–1722.
    1. Verweij KJ, Vinkhuyzen AA, Benyamin B, Lynskey MT, Quaye L, Agrawal A et al (2013. b). The genetic aetiology of cannabis use initiation: a meta-analysis of genome-wide association studies and a SNP-based heritability estimation. Addict Biol 18: 846–850.
    1. Volkow ND, Baler RD, Compton WM, Weiss SR (2014). Adverse health effects of marijuana use. N Engl J Med 370: 2219–2227.
    1. Volkow ND, Compton WM, Wargo EM (2017). The risks of marijuana use during pregnancy. JAMA 317: 129–130.
    1. Volkow ND, McLellan AT (2016). Opioid abuse in chronic pain—misconceptions and mitigation strategies. N Engl J Med 374: 1253–1263.
    1. Volkow ND, Swanson JM, Evins AE, DeLisi LE, Meier MH, Gonzalez R et al (2016). Effects of cannabis use on human behavior, including cognition, motivation, and psychosis: a review. JAMA Psychiatry 73: 292–297.
    1. Wall MM, Poh E, Cerda M, Keyes KM, Galea S, Hasin DS (2011). Adolescent marijuana use from 2002 to 2008: higher in states with medical marijuana laws, cause still unclear. Ann Epidemiol 21: 714–716.
    1. Walsh Z, Callaway R, Belle-Isle L, Capler R, Kay R, Lucas P et al (2013). Cannabis for therapeutic purposes: patient characteristics, access, and reasons for use. Int J Drug Policy 24: 511–516.
    1. Walsh Z, Gonzalez R, Crosby K, S Thiessen M, Carroll C, Bonn-Miller MO (2017). Medical cannabis and mental health: a guided systematic review. Clin Psychol Rev 51: 15–29.
    1. Wang GS, Hall K, Vigil D, Banerji S, Monte A, VanDyke M (2017). Marijuana and acute health care contacts in Colorado. Prev Med. pii: S0091-7435(17)30120-2.
    1. Wang GS, Le Lait MC, Deakyne SJ, Bronstein AC, Bajaj L, Roosevelt G (2016. a). Unintentional pediatric exposures to marijuana in Colorado, 2009-2015. JAMA Pediatr 170: e160971.
    1. Wang GS, Roosevelt G, Le Lait MC, Martinez EM, Bucher-Bartelson B, Bronstein AC et al (2014). Association of unintentional pediatric exposures with decriminalization of marijuana in the United States. Ann Emerg Med 63: 684–689.
    1. Wang JB, Ramo DE, Lisha NE, Cataldo JK (2016. b). Medical marijuana legalization and cigarette and marijuana co-use in adolescents and adults. Drug Alcohol Depend 166: 32–38.
    1. Washington State Marijuana Impact Report (2016). Available at Accessed 2 July 2017.
    1. The Washington Times (2016). Marijuana sales in Washington state top $1 billion: Report. Available at: Accessed 30 June 2017.
    1. Watson TM, Mann RE (2016). International approaches to driving under the influence of cannabis: a review of evidence on impact. Drug Alcohol Depend 169: 148–155.
    1. Weiss SRB, Blanco C, Wargo EM (2017). Clarifying the link between cannabis use and risk for psychosis. Acta Psychiatr Scand 136: 3–4.
    1. Wen H, Hockenberry JM, Cummings JR (2015). The effect of medical marijuana laws on adolescent and adult use of marijuana, alcohol, and other substances. J Health Econ 42: 64–80.
    1. Wettlaufer A, Florica RO, Asbridge M, Beirness D, Brubacher J, Callaghan R et al (2017). Estimating the harms and costs of cannabis-attributable collisions in the Canadian provinces. Drug Alcohol Depend 173: 185–190.
    1. Whiting PF, Wolff RF, Deshpande S, Di Nisio M, Duffy S, Hernandez AV et al (2015). Cannabinoids for medical use: a systematic review and meta-analysis. JAMA 313: 2456–2473.
    1. Wilkinson ST, Stefanovics E, Rosenheck RA (2015). Marijuana use is associated with worse outcomes in symptom severity and violent behavior in patients with posttraumatic stress disorder. J Clin Psychiatry 76: 1174–1180.
    1. Williams AR, Olfson M, Kim JH, Martins SS, Kleber HD (2016). Older, less regulated medical marijuana programs have much greater enrollment rates than newer 'medicalized' programs. Health Aff (Millwood) 35: 480–488.
    1. Williams AR, Santaella-Tenorio J, Mauro CM, Levin FR, Martins SS (2017). Loose regulation of medical marijuana programs associated with higher rates of adult marijuana use but not cannabis use disorder. Addiction. doi: 10.1111/add.13904.
    1. World Health Organization (1992) International Statistical Classification of Diseases and Related Health Problems, 10th revision. ed. World Health Organization: Geneva.
    1. Wu CS, Jew CP, Lu HC (2011). Lasting impacts of prenatal cannabis exposure and the role of endogenous cannabinoids in the developing brain. Future Neurol 6: 459–480.
    1. Wu LT, Zhu H, Mannelli P, Swartz MS (2017). Prevalence and correlates of treatment utilization among adults with cannabis use disorder in the United States. Drug Alcohol Depend 177: 153–162.
    1. Zalesky A, Solowij N, Yucel M, Lubman DI, Takagi M, Harding IH et al (2012). Effect of long-term cannabis use on axonal fibre connectivity. Brain 135(Pt 7): 2245–2255.
    1. Zammit S, Allebeck P, Andreasson S, Lundberg I, Lewis G (2002). Self reported cannabis use as a risk factor for schizophrenia in Swedish conscripts of 1969: historical cohort study. BMJ 325: 1199.
    1. Zhu H, Wu LT (2016). Trends and correlates of cannabis-involved emergency department visits: 2004 to 2011. J Addict Med 10: 429–436.

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe